Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891262 | 0.89 | KCNA5 (0.43) | KCNA5NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2889346 | 0.89 | KCNA5 (0.44) | KCNA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2891657 | 0.88 | KCNA5 (0.44) | KCNA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2883788 | 0.87 | KCNA5 (0.43) | KCNA5NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL2883678 | 0.85 | KCNA5 (0.46) | KCNA5LMNAGAAHTT | |
| SCHEMBL2888950 | 0.85 | KCNA5 (0.42) | KCNA5NPC1RAB9ATAAR1GAA | |
| SCHEMBL2891148 | 0.84 | SMN1; SMN2 (0.48) | KCNA5NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2887356 | 0.84 | KCNA5 (0.55) | KCNA5RAB9AMEN1KMT2AGAA | |
| SCHEMBL2891901 | 0.83 | NPC1 (0.41) | KCNA5NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5661824 | 0.83 | KCNA5 (0.41) | KCNA5NPC1RAB9ATAAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | KCNA5 69/4885NPC1 3993/4885RAB9A 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.